Related Experiment Video
Updated: Apr 21, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm
Shannon W Finks1, Jennifer D Campbell
1Shannon W. Finks is an associate professor at the University of Tennessee, College of Pharmacy, Memphis, Tenn. Jennifer D. Campbell is a Clinical Pharmacist of Ambulatory Care at Regional Medical Center, Memphis, Tenn.
The Nurse Practitioner
|October 18, 2014
Summary
Nearly half of serious adverse events from statin therapy stem from dangerous drug-drug interactions. This review covers updated FDA warnings, labeling changes for statins interacting with CYP3A4 inhibitors, and renal dosing guidelines.
Area of Science:
- Pharmacology
- Drug Safety
- Clinical Pharmacy
Background:
- Statin therapy is widely used for cardiovascular disease prevention.
- Serious adverse events (SAEs) are a concern with statin use.
- Drug-drug interactions (DDIs) contribute significantly to statin-related SAEs.
Purpose of the Study:
- To review updated FDA warnings regarding statin therapy.
- To highlight recent changes in statin labeling concerning DDIs.
- To provide current recommendations for renal dosing of statins.
Main Methods:
- Review of updated US Food and Drug Administration (FDA) warnings.
- Analysis of recent changes in prescribing information for statins.
- Compilation of current renal dosing guidelines for statins.
Main Results:
- Significant percentage of SAEs linked to DDIs with statins.
- Specific warnings issued on dose capping for simvastatin.
- Labeling updates address interactions with potent cytochrome P450 (CYP3A4) inhibitors.
- Current renal dosing recommendations are provided.
Conclusions:
- Awareness of DDIs is crucial for safe statin prescribing.
- Updated FDA guidance and labeling changes aid in mitigating risks.
- Adherence to renal dosing recommendations is essential for specific patient populations.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:30Drug toxicity: Drug–Drug Interaction
405
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
405
01:25Pharmacokinetics: Drug–Drug Interactions
792
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
792
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
651
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
651
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
720
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
720
01:24Drug Toxicity: Risk factors
225
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
225